Third Rock Ventures’ Post

BC Partners has put Synthon up for sale, appointing Rothschild & Co, Barclays and Latham & Watkins as it presses ahead with its selling spree. Read the full story from Edin Imsirovic below

Outstanding program and panel discussion last night hosted by Ryan Dolan and CFGI on the Capital Markets Landscape within the Boston Life Sciences ecosystem along with insights from former Chairman of the SEC, Jay Clayton. The discussion included a retrospective on companies prepared for IPO's and a look forward at what positive movement in interest rates could mean for increased activity in 2025. The biotech community was out in full force and it was great running into faces new and old. #LifeSciences #CapitalMarkets #MMALifeSciencesPractice

In this edition of Premier Miton Investors Talking Markets, host Jonathan Willcocks and Benji Dawes, Fund Manager of the Premier Miton UK Growth Fund and Premier Miton Responsible UK Equity Fund, discuss UK #Equities 👉 https://lnkd.in/eW_wvP_G Along with navigating current market challenges, avoiding pitfalls, and where Benji is seeing opportunities.

Excited to share a panel recap from the recent PBC Group - Organisers of the COG Series New England Conference💡! 🔍 From redefining inflection points to leveraging personal connections (hello, unexpected Zoom calls from Formula 1 bosses), we had 8 CEOs share their perspectives on funding clinical-stage biotechs. 💰 What options are available outside the traditional VC and IPO routes? Should vendors have skin in the game? 📈 Back and forth concerning cost-sharing vs. equity deals and explore the pros and cons of shipping trials to Australia (spoiler alert: turns out that koalas will not cover R&D bills 🐨). 🔥 Hot Take: Non-dilutive funding doesn't truly exist #BiotechFunding #CreativeFinancing #COG https://lnkd.in/eBYZtw5q

As the JPMorgan healthcare conference approaches, Mike Gaito, JPMorgan's Global Head of Healthcare Investment Banking, paints an optimistic picture for the sector in 2024. He foresees a buoyant atmosphere for healthcare mergers and acquisitions, expecting broader participation from various verticals beyond biopharma. The current momentum in biopharma, particularly in cardio-metabolic treatments and groundbreaking oncology advancements, is anticipated to persist. Gaito highlights the potential growth in medtech, life sciences, and diagnostics sectors, provided that the market rebounds and economic conditions remain favorable. While acknowledging the U.S. presidential election's spotlight on drug pricing, he suggests it won't significantly sway decision-making in the M&A landscape. Expectations linger for significant acquisitions, albeit challenges persist for substantial mergers in the face of intensified regulatory scrutiny. Intriguing conversations are brewing around the potential disruptions fueled by AI and the implications of GLP-1s across multiple industry domains. 🚀 #HealthcareIndustry #JPMorganConference"

A big thanks to Jordan Saxe ⛷️ for doing an exceptional job moderating the "Charting the Biotech IPO Frontier” panel at the #FierceBiotechSummit earlier this week. We had an all-star group of panelists, including Andrew W. Lam, PharmD, Troy Ignelzi, Alethia Young and Divakar Gupta. We discussed how the path to an IPO has evolved; it is now a much longer road that requires a lot of strategic groundwork. In today's environment, building strong relationships early is critical. It’s about finding the right partners - the bankers, lawyers, analysts and other advisors - who really understand your space and can help guide you through the intricacies of the process. Another key takeaway? The importance of storytelling. It’s not enough to have a good product—you need to communicate it simply and effectively, and build credibility over time. In the end, while an IPO is a major milestone, it’s just a starting point that opens the door to even greater opportunities. Thanks again to Michelle Benz and Chris Hayden at Fierce Life Sciences Events for running a fantastic event! #Biotech #IPO #LifeSciences #CapitalMarkets #StrategicPlanning

Nothing for the Swim Home: How The Entelechy of Cannabis Companies Is Shaping Their Future Success. Shifting focus from the "A-pot-calypse" to a more optimistic outlook for the cannabis industry's future, Merida Capital Holdings’ Founder and Managing Partner Mitchell Baruchowitz emphasizes the resilience and strategic acumen of "thrivalists," firms that have not only survived but thrived, attributing their success to a no-looking-back philosophy and essential insights for navigating the industry's challenges from 2021 to 2024. In his latest commentary, Mitch underlines the importance of leveraging the lessons learned during the industry's rapid evolution and the critical role of adapting to market demands and operational efficiencies. https://lnkd.in/evAK4Vr5

Eric Espinoza VP at Green Life Business, weighs in on the new opportunities arising in the cannabis space during the main stage M&A panel at Benzinga Cannabis's Capital Conference: There is a lot of consolidation in California, we believe there is opportunity in stressed environments. "Even though there are hard deals, there are also gems popping out in the West Coast, especially in California.” Espinoza calls these distressed companies “gems,” or companies that have called for offers because they need of capital. He mentioned that these situations might lead to picking up valuable companies for pennies on the dollar, noting that interesting investor spaces can be found on the West Coast, California, Nevada and the East Coast in New York, Florida and Ohio. Catch the fascinating full panel discussion: https://lnkd.in/g45B4wPU #benzinga #miami #industry #cannabis #benzingacannabisconference #capital #investing #cannabisindustry #leaders

Corporate and M&A partner, Eoghan Doyle, featured in yesterday’s Business Post commenting on how Ireland is bucking the trend in M&A. "If you look at the M&A market in 2023, it was very positive generally for Ireland in terms of transactional volumes. And that trend is continuing into this year. There's still plenty of activity in the market, with a lot of deals done in the first quarter." Read the full article here: https://lnkd.in/eJg9xC24 #MergersandAcquisitions #PrivateEquity #Ireland

PitchBook's Institutional Research Group has just released the February edition of the Monthly Market Update. In this edition, you’ll learn about resilient PE fundraising, surging Biopharma IPOs, and the historically high volume of loan repricing activity. Meanwhile, late-stage valuations have begun to tick upwards, which hopefully portends a reversal in returns that have lagged the rest of private capital in recent quarters.